动脉灌注多西他赛和表柔比星治疗乳腺癌术后胸壁复发的远期效果分析  

Long term effect of arterial infusion of docetaxel and epirubicin in the treatment of breast cancer with chest wall recurrence after operation

作　　者：董久兴 赵佳[2] 刘琪[1] 熊露宁[1] 齐秀恒[1] 邹庆华[1] 

机构地区：[1]中国石油天然气集团公司中心医院肿瘤科,河北廊坊065000 [2]中国石油天然气集团公司中心医院急诊科,河北廊坊065000

出　　处：《现代肿瘤医学》2017年第21期3435-3438,共4页Journal of Modern Oncology

基　　金：廊坊市科技支撑计划项目(编号:2015013002C)

摘　　要：目的:分析动脉灌注多西他赛和表柔比星治疗乳腺癌术后胸壁复发(CWR)的远期效果。方法:选择2013年10月至2016年1月期间,参加我院动脉灌注多西他赛和表柔比星治疗乳腺癌术后胸壁复发临床试验的患者为研究对象。研究组(Ⅰ组):动脉灌注化疗药物组,共25例;对照组(Ⅱ组):中心静脉输入化疗药物组,共40例。通过随访,记录患者病灶局部进展的时间(胸壁复发病灶进展或区域淋巴结转移的时间)、出现远处转移的时间及死亡时间,对两组患者的统计数据进行生存分析。结果:全组患者随访9~36个月,中位随访23个月,对随访数据进行生存分析:Ⅰ组、Ⅱ组的中位无进展生存期(PFS)分别为11个月、7个月,差异有统计学意义(P=0.03);Ⅰ组、Ⅱ组的中位无远处转移生存期(DMFS)分别为17个月、14个月,差异无统计学意义(P=0.33);Ⅰ组、Ⅱ组的中位总生存期(OS)分别为47个月、44个月,差异无统计学意义(P=0.71)。结论:经动脉灌注化疗,延长了乳腺癌术后胸壁复发患者的PFS,在DMFS及OS上两者差异不显著。远期效果略优于静脉化疗。Objective ：To analyze the long term effect of artery infusion of docetaxel, epirubicin than traditional in- travenous chemotherapy, on the chest wall recurrence after treatment of breast cancer patients （ radical, modified radi- cal mastectomy）. Methods：From October 2013 to January 2016 in our hospital. To analyze the effect and side reac- tion of artery infusion of docetaxel, epirubicin than traditional intravenous chemotherapy, on the chest wall recurrence after treatment of breast cancer patients （radical, modified radical mastectomy）. Select the patients in each group of the research object. Study group （group I） ：Arterial infusion chemotherapy drug group, a total of 25 cases. Control group （group 1I ） ：Central venous infusion chemotherapy drug group,a total of 40 cases. Through the follow- up,the time of local progress（ the time of chest wall recurrence progress or regional lymph node metastasis） ,the time of dis- tant metastasis and the time of death were recorded. The survival analysis was carried out on the two groups of pa- tients. Results ： All patients were followed up for 9 N 36 months, with a median follow - up of 23 months. Survival anal- ysis ： Group I, group 11, median progression free survival （PFS） for 11 months,7 months, the difference was statisti- cally significant（P = 0.03 ）. Median distant metastasis free survival （DMFS） for 17 months, 14 months ,the difference was not statistically significant（ P = O. 33 ）. Median overall survival （OS） for 47 months ,44 months ,the difference was not statistically significant （P = 0.71 ）. Conclusion：After arterial infusion chemotherapy prolongs progression free sur- vival in breast cancer patients with chest wall recurrence, and the data had statistical significance. While distant me- tastasis free survival and total survival time there is a difference, but not significant. Long term effect was slightly bet- ter than intravenous chemotherapy.

关 键 词：乳腺癌 胸壁复发 动脉灌注 化疗 生存分析 

分 类 号：R737.9[医药卫生—肿瘤]